Last $36.85 USD
Change Today -0.75 / -1.99%
Volume 651.1K
PODD On Other Exchanges
As of 4:30 PM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

insulet corp (PODD) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/21/14 - $51.31
52 Week Low
08/8/14 - $30.04
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for INSULET CORP (PODD)

insulet corp (PODD) Related Bloomberg News

View More Bloomberg News

insulet corp (PODD) Related Businessweek News

No Related Businessweek News Found

insulet corp (PODD) Details

Insulet Corporation develops, manufactures, and sells insulin infusion systems for people with insulin-dependent diabetes in the United States. The company offers OmniPod Insulin Management System (OmniPod System), which consists of the OmniPod, a disposable insulin infusion device that integrates an infusion set, automated cannula insertion, insulin reservoir, drive mechanism, and batteries; and a handheld, wireless personal diabetes manager. It is also involved in the distribution of durable medical equipment, including blood glucose testing supplies, insulin pumps, pump supplies, pharmaceuticals, and other products for the management and treatment of diabetes. The company sells its OmniPod System directly to patients through referrals from healthcare professionals and through patient leads, as well as through third-party distributors. Insulet Corporation was founded in 2000 and is based in Bedford, Massachusetts.

478 Employees
Last Reported Date: 02/28/14
Founded in 2000

insulet corp (PODD) Top Compensated Officers

Chief Financial Officer and Principal Account...
Total Annual Compensation: $330.4K
Chief Commercial Officer
Total Annual Compensation: $306.3K
Director of Advanced Technology and Director
Total Annual Compensation: $376.9K
General Counsel and Secretary
Total Annual Compensation: $265.0K
Total Annual Compensation: $448.4K
Compensation as of Fiscal Year 2013.

insulet corp (PODD) Key Developments

Insulet Corporation Appoints Patrick J. Sullivan as President and Chief Executive Officer

Insulet Corporation announced that Patrick J. Sullivan has been appointed President and Chief Executive Officer, and Director effective immediately. Mr. Sullivan succeeds Duane DeSisto, who is retiring after 13 years at the Company. Mr. DeSisto will be available to the Company as a consultant through the end of 2014 to assist with an effective leadership transition. Mr. Sullivan brings more than 30 years of executive leadership experience to Insulet. As Chairman, President and CEO of Cytyc Corporation from 1994 to 2007. He continues to serve as a director of PerkinElmer Inc.

Insulet Corporation and DexCom to Develop CGM-Integrated Diabetes Manager

Insulet Corporation and DexCom, Inc. have agreed to develop a CGM-integrated personal diabetes manager. This will allow information from Dexcom's 5th generation CGM system to be identified, received and displayed on Insulet's new Bluetooth-enabled Personal Diabetes Manager. This project expands upon the initial agreement announced in June to enable the Dexcom mobile app platform to integrate data from Insulet's OmniPod System. That platform to enable glucose and pump data to be displayed on a smartphone.

Insulet Appoints Timothy J. Scannell to Board of Directors

Insulet Corporation announced the appointment of Timothy J. Scannell to the company's board of directors. Mr. Scannell currently serves as Group President, MedSurg & Neurotechnology at Stryker Corporation. Mr. Scannell's general management responsibilities at Stryker date back to 2001, and since 2008 he has served as group president overseeing multiple global businesses including Neurotechnology, Endoscopy, Medical, Sustainability Solutions, Instruments and CMF. Mr. Scannell served as General Manager and President of Stryker Spine from 2003 to 2008 and led all functions of the business.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PODD:US $36.85 USD -0.75

PODD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $113.81 USD -0.54
DexCom Inc $39.99 USD -1.40
Smiths Group PLC 1,264 GBp +14.00
Takeda Pharmaceutical Co Ltd ¥4,768 JPY -44.00
Tandem Diabetes Care Inc $13.42 USD +0.22
View Industry Companies

Industry Analysis


Industry Average

Valuation PODD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.7x
Price/Book 26.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INSULET CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at